https://pubmed.ncbi.nlm.nih.gov/?term=Winton%20EF%5Bauth%5D
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia. Jillella AP Arellano ML Gaddh M Langston AA Heffner LT Winton EF, McLemore ML Zhang C Caprara CR Simon KS Bolds SL DeBragga S Karkhanis P Krishnamurthy SH Tongol J El Geneidy MM Pati A Gerber JM Grunwald MR Cortes J Bashey A Stuart RK Kota VK . JCO oncology practice OP2000395 2020-10-30
Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera. Coltoff A Mesa R Gotlib J Shulman J Rampal RK Siwoski O Yacoub A Moliterno A Yang A Braunstein E Gerds AT Hobbs GS Winton EF, Goel S Wadleigh M Tremblay D Moshier E Mascarenhas J . Clinical lymphoma, myeloma & leukemia 20 10 697-703.e1 2020-10-01
Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors. Kong JH Winton EF, Heffner LT Gaddh M Hill B Neely J Hatcher A Joseph M Arellano M El-Rassi F Kim A Khoury JH Kota VK . Journal of clinical medicine 9 5 2020-05-20
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Yacoub A Mascarenhas J Kosiorek H Prchal JT Berenzon D Baer MR Ritchie E Silver RT Kessler C Winton E, Finazzi MC Rambaldi A Vannucchi AM Leibowitz D Rondelli D Arcasoy MO Catchatourian R Vadakara J Rosti V Hexner E Kremyanskaya M Sandy L Tripodi J Najfeld V Farnoud N Papaemmanuil E Salama M Singer-Weinberg R Rampal R Goldberg JD Barbui T Mesa R Dueck AC Hoffman R . Blood 134 18 1498-1509 2019-10-31
Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. Khoury HJ Langston AA Kota VK Wilkinson JA Pusic I Jillella A Bauer S Kim AS Roberts D Al-Kadhimi Z Bodo I Winton E, Arellano M DiPersio JF . Bone marrow transplantation 53 7 826-831 2018-07-01
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Harrison CN Vannucchi AM Platzbecker U Cervantes F Gupta V Lavie D Passamonti F Winton EF, Dong H Kawashima J Maltzman JD Kiladjian JJ Verstovsek S . The Lancet. Haematology 5 2 e73-e81 2018-02-01
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. Mesa RA Kiladjian JJ Catalano JV Devos T Egyed M Hellmann A McLornan D Shimoda K Winton EF, Deng W Dubowy RL Maltzman JD Cervantes F Gotlib J . Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35 34 3844-3850 2017-12-01
Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib. Kota VK Kong JH Arellano M El Rassi F Gaddh M Heffner LT Winton EF, Jillella AP McLemore ML Khoury HJ . Clinical lymphoma, myeloma & leukemia 17 12 e71-e73 2017-12-01
Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia? Kong JH Winton EF, Heffner LT Chen Z Langston AA Hill B Arellano M El-Rassi F Kim A Jillella A Kota VK Bodó I Khoury HJ . Cancer 123 13 2482-2488 2017-07-01
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Harrison CN Schaap N Vannucchi AM Kiladjian JJ Tiu RV Zachee P Jourdan E Winton E, Silver RT Schouten HC Passamonti F Zweegman S Talpaz M Lager J Shun Z Mesa RA . The Lancet. Haematology 4 7 e317-e324 2017-07-01
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. Verstovsek S Mesa RA Gotlib J Gupta V DiPersio JF Catalano JV Deininger MW Miller CB Silver RT Talpaz M Winton EF, Harvey Jr JH Arcasoy MO Hexner EO Lyons RM Paquette R Raza A Jones M Kornacki D Sun K Kantarjian H . Journal of hematology & oncology 10 1 55 2017-02-22
Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia. Winton EF, Kota V . Future oncology (London, England) 13 5 395-407 2017-02-01
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Mascarenhas JO Talpaz M Gupta V Foltz LM Savona MR Paquette R Turner AR Coughlin P Winton E, Burn TC O'Neill P Clark J Hunter D Assad A Hoffman R Verstovsek S . Haematologica 102 2 327-335 2017-02-01
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. Cohen JB Bucur S, Winton EF Sinha R Heffner LT King N Lonial S Langston AA Waller EK Hutchison-Rzepka A Colbert A Lechowicz MJ Flowers CR . Clinical lymphoma, myeloma & leukemia 15 9 514-8 2015-09-01
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Verstovsek S, Mesa RA Gotlib J Levy RS Gupta V DiPersio JF Catalano JV Deininger MW Miller CB Silver RT Talpaz M Winton EF Harvey Jr JH Arcasoy MO Hexner EO Lyons RM Raza A Vaddi K Sun W Peng W Sandor V Kantarjian H . Haematologica 100 4 479-88 2015-04-01
Predicting early blast transformation in chronic-phase chronic myeloid leukemia: is immunophenotyping the missing link? El Rassi F Bergsagel JD Arellano M Gaddh M Jillella A Kota V Heffner LT Winton EF Khoury HJ, . Cancer 121 6 872-5 2015-03-15
Incidence and geographic distribution of adult acute leukemia in the state of Georgia. El Rassi F Ward KC Flowers CR Heffner LT Waller EK, Winton EF Vaughn J Hill BG Langston A Nooka A Arellano M Khoury HJ . Southern medical journal 107 8 497-500 2014-08-01
Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma. Mitri Z Siddiqui MT El Rassi F Holden JT Heffner LT Langston A Waller EK Winton E McLemore M Bernal-Mizrachi L Jaye D Arellano M Khoury HJ, . Leukemia & lymphoma 55 7 1498-500 2014-07-01
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Mesa RA Kiladjian JJ Verstovsek S Al-Ali HK Gotlib J Gisslinger H Levy R Siulnik A Gupta V Khan M DiPersio JF McQuitty M Catalano JV Hunter DS Knoops L Deininger M Cervantes F Miller C Vannucchi AM Silver RT Barbui T Talpaz M Barosi G Winton EF, Mendeson E Harvey Jr JH Arcasoy MO Hexner E Lyons RM Paquette R Raza A Sun W Sandor V Kantarjian HM Harrison C . Haematologica 99 2 292-8 2014-02-01
Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. Dao KH, Solti MB Maxson JE Winton EF Press RD Druker BJ Tyner JW . Leukemia research reports 3 2 67-9 2014-01-01
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Verstovsek S Mesa RA Gotlib J Levy RS Gupta V DiPersio JF Catalano JV Deininger MW Miller CB Silver RT Talpaz M Winton EF, Harvey Jr JH Arcasoy MO Hexner EO Lyons RM Paquette R Raza A Vaddi K Erickson-Viitanen S Sun W Sandor V Kantarjian HM . Haematologica 98 12 1865-71 2013-12-01
Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. Antun AG Gleason S Arellano M Langston AA McLemore ML Gaddh M el Rassi F Bernal-Mizrachi Jr L Galipeau J, Heffner LT Winton EF Khoury HJ . Cancer 119 21 3784-7 2013-11-01
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Verstovsek S Mesa RA Gotlib J Levy RS Gupta V DiPersio JF Catalano JV Deininger M Miller C Silver RT Talpaz M Winton EF, Harvey Jr JH Arcasoy MO Hexner E Lyons RM Paquette R Raza A Vaddi K Erickson-Viitanen S Sun W Sandor V Kantarjian HM . British journal of haematology 161 4 508-16 2013-05-01
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. Mesa RA Gotlib J Gupta V Catalano JV Deininger MW Shields AL Miller CB Silver RT Talpaz M Winton EF, Harvey JH Hare T Erickson-Viitanen S Sun W Sandor V Levy RS Kantarjian HM Verstovsek S . Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31 10 1285-92 2013-04-01
Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia. Arellano M Pakkala S Langston A Tighiouart M Pan L Chen Z Heffner LT Lonial S, Winton E Khoury HJ . Cancer 118 21 5278-82 2012-11-01
Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. Muringampurath-John D Jaye DL Flowers CR Saxe D Chen Z Lechowicz MJ Weisenburger DD Bast M Arellano ML Bernal-Mizrachi L Heffner LT, McLemore M Kaufman JL Winton EF Lonial S Armitage JO Khoury HJ . British journal of haematology 158 5 608-14 2012-09-01
Managing chronic myeloid leukemia: a coordinated team care perspective. Holloway S Lord K Bethelmie-Bryan B, Shepard MW Neely J McLemore M Reddy SK Montero A Jonas WS Gladney SP Khanwani SL Reddy SC Lahiry AK Heffner LT Winton E Arellano M Khoury HJ . Clinical lymphoma, myeloma & leukemia 12 2 88-93 2012-04-01
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. Muringampurath-John D Flowers CR Toscano M Zhengjia C Kaufman JL Arellano M Bernal-Mizrachi L Heffner LT Lechowicz MJ McLemore M Winton E Jaye DL Lonial S Khoury HJ, . Leukemia & lymphoma 53 4 725-7 2012-04-01
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. Verstovsek S Mesa RA Gotlib J Levy RS Gupta V DiPersio JF Catalano JV Deininger M Miller C Silver RT Talpaz M Winton EF, Harvey Jr JH Arcasoy MO Hexner E Lyons RM Paquette R Raza A Vaddi K Erickson-Viitanen S Koumenis IL Sun W Sandor V Kantarjian HM . The New England journal of medicine 366 9 799-807 2012-03-01
High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years. Arellano M Winton E, Pan L Lima L Tighiouart M Bhalla K Heffner LT Neely J Hutcherson D McLemore M Langston A Khoury HJ . Cancer 118 2 428-33 2012-01-15
Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia. Arellano M Bernal-Mizrachi L Pan L Tighiouart M Souza L Guo X McLemore M Lima L Sunay S, Heffner LT Chen Z Chen GZ Langston A Winton E Khoury HJ . Clinical lymphoma, myeloma & leukemia 11 5 427-32 2011-10-01
Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia? Lima LM Sampat K Assouline S Saxe D Nault S, Tighiouart M McLemore M Arellano M Winton E Bernal-Mizrachi L Cortes J Khoury HJ . Leukemia & lymphoma 52 6 1010-6 2011-06-01
Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Lima L Bernal-Mizrachi L Saxe D Mann KP Tighiouart M Arellano M Heffner L McLemore M Langston A, Winton E Khoury HJ . Cancer 117 6 1245-52 2011-03-15
Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters. Tran H Arellano M Chamsuddin A Flowers C Heffner LT Langston A Lechowicz MJ, Tindol A Waller E Winton EF Khoury HJ . Leukemia & lymphoma 51 8 1473-7 2010-08-01
Spectrum of FDG PET/CT findings in Burkitt lymphoma. Zeng W Lechowicz MJ, Winton E Cho SM Galt JR Halkar R . Clinical nuclear medicine 34 6 355-8 2009-06-01
Acquired copper deficiency: a potentially serious and preventable complication following gastric bypass surgery. Griffith DP, Liff DA Ziegler TR Esper GJ Winton EF . Obesity (Silver Spring, Md.) 17 4 827-31 2009-04-01
Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma. Murali S Winton E, Waller EK Heffner LT Lonial S Flowers C Kaufman J Arellano M Lechowicz MJ Mann KP Khoury HJ Langston AA . Bone marrow transplantation 42 8 529-34 2008-10-01
Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma. Lonial S Arellano M Hutcherson D Langston A Flowers C Heffner LT Winton E, Jo Lechowicz M Waller EK . Leukemia & lymphoma 47 10 2155-62 2006-10-01
